
argenx (ARGX) Stock Forecast & Price Target
argenx (ARGX) Analyst Ratings
Bulls say
Argenx has experienced significant topline growth, with Q1 2025 revenue reaching $790 million, representing a 98% year-over-year increase, and Q2 2025 revenue of $949 million, reflecting a 97% year-over-year increase, driven primarily by the adoption of its pre-filled syringe format and expanded use in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company's innovative approach has been validated by promising clinical results, with phase Ib trials of ARGX-119 demonstrating clinically meaningful improvements in key measures, further positioning the company for a registrational Phase III trial in 2026. Additionally, the focus on label expansion opportunities in seronegative and pediatric forms of MG, along with increased prescriber engagement, suggests a robust growth trajectory supported by strong market demand for its therapies.
Bears say
Argenx faces several significant risks that contribute to a negative outlook on its stock, notably the potential for lower-than-anticipated growth in sales of its lead product, Vyvgart, and the possibility of unforeseen safety signals emerging during ongoing clinical trials. Additional factors include the threat of increased competition in the biopharmaceutical market, as well as broader macroeconomic challenges such as foreign exchange fluctuations, inflation, and shipping-related issues. Furthermore, the company's reliance on the successful penetration of new target populations for Vyvgart and its ongoing pipeline development raises concerns about the feasibility of achieving its projected market share, particularly in niche therapeutic areas.
This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.
argenx (ARGX) Analyst Forecast & Price Prediction
Start investing in argenx (ARGX)
Order type
Buy in
Order amount
Est. shares
0 shares